
<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0">
    <title>GI Intelligence Terminal</title><script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        body { font-family: -apple-system, sans-serif; background:#f5f7fa; color:#2c3e50; margin:0; padding:10px; }
        .card { background:#fff; border-radius:12px; padding:15px; box-shadow:0 2px 8px rgba(0,0,0,0.05); margin-bottom:15px; border:1px solid #e0e0e0; }
        .paper-item { background:#fff; border:1px solid #eee; margin-bottom:8px; border-radius:10px; border-left:4px solid #3498db; overflow:hidden; }
        summary { padding:12px; cursor:pointer; list-style:none; outline:none; }
        summary::-webkit-details-marker { display:none; }
        .meta { font-size:0.75rem; color:#7f8c8d; margin-bottom:5px; display:flex; align-items:center; gap:5px; flex-wrap:wrap; }
        .title { font-weight:bold; font-size:0.95rem; line-height:1.4; }
        .arrow { display:inline-block; transition:0.2s; color:#3498db; margin-right:5px; }
        details[open] .arrow { transform:rotate(90deg); }
        .badge { padding:2px 5px; border-radius:4px; font-size:0.65rem; font-weight:bold; color:#fff; }
        .rct { background:#e74c3c; } .gl { background:#2ecc71; } .if { background:#8e44ad; } .endo { background:#9b59b6; }
        .content { padding:15px; background:#f9f9f9; border-top:1px solid #eee; font-size:0.9rem; }
        .clinical-note { background:#fff8e1; border:1px solid #ffe082; padding:12px; border-radius:8px; margin-bottom:12px; color:#5d4037; font-size:0.85rem; border-left:4px solid #ffb300; }
        .btm-box { background:#ebf5ff; padding:12px; border-radius:8px; margin-bottom:12px; border-left:4px solid #3498db; font-weight:bold; }
        .btns { display:flex; gap:10px; margin-top:15px; }
        .btn { flex:1; padding:10px; border-radius:6px; text-align:center; text-decoration:none; font-weight:bold; border:none; cursor:pointer; font-size:0.85rem; color:#fff; }
        .pub { background:#3498db; } .shr { background:#2ecc71; }
        .filter-btn { width:100%; padding:12px; border-radius:20px; border:2px solid #2ecc71; background:#fff; color:#2ecc71; font-weight:bold; cursor:pointer; margin-bottom:15px; }
        .filter-btn.active { background:#2ecc71; color:#fff; }
    </style>
</head>
<body>
    <div class="card" style="text-align:center;">
        <h1 style="margin:0; font-size:1.6rem;">ğŸ¥ GI Intelligence Terminal</h1>
        <div style="margin-top:8px;"><span style="background:#ebf5ff; color:#3498db; padding:4px 12px; border-radius:15px; font-size:0.75rem; font-weight:bold;">Updated: 2026-02-26 14:29 KST</span></div>
    </div>
    <div style="display:grid; grid-template-columns: 1fr 1fr; gap:10px;">
        <div class="card"><canvas id="c1" style="height:120px;"></canvas></div>
        <div class="card"><canvas id="c2" style="height:120px;"></canvas></div>
    </div>
    <div class="card">
        <button id="fBtn" class="filter-btn" onclick="toggleF()">ğŸ“‹ ê°€ì´ë“œë¼ì¸ë§Œ ë³´ê¸°</button>
        <div class='sec-group'><h3>ğŸ GI Track</h3>
        <details class="paper-item">
            <summary>
                <div class="meta">ğŸ‘‘ <span class='badge if'>IF 29.4</span> <b>The American journal of gastroenterology</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Letter to the Editor.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs"></div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41738651/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41738651')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41738651" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Letter to the Editor.\nğŸ“– The American journal of gastroenterology (IF:29.4)\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738651/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus</b>  ğŸ”¥</div>
                <div class="title"><span class="arrow">â–¶</span>Lymph node yield and its impact on survival outcomes: a retrospective multicenter cohort study from Denmark.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> âš ï¸ ê¸°ì¡´ ì¹˜ë£Œ ìœ ì§€ ê¶Œì¥</div>
        </div>
                
                <div class="abs">The prognostic value of lymph node (LN) yield in esophageal and gastric cancer remains controversial, especially in the context of modern perioperative treatment. This multicenter Danish cohort study evaluates the association between LN yield and survival outcomes. This study included 3092 patients who underwent curative-intent resection for esophageal (nâ€‰=â€‰2402) or gastric cancer (nâ€‰=â€‰690) between 2013 and 2021 at four Danish upper GI centers. All cases were registered in the Danish Esophagogastric Cancer Group database, covering 99% of all Danish esophageal and gastric cancer cases. Patients were stratified by nodal status (pN0/pN+) and categorized into five LN yield groups. Survival analyses were performed using Kaplan-Meier curves and multivariable Cox regression. In node-negative esophageal cancer, higher LN yields (20-29, 30-39, and 40+) were significantly associated with improved survival (hazard ratio: 0.47-0.58, Pâ€‰<â€‰0.001) compared with the reference group (16-19). No survival benefit was seen beyond 16-19 nodes in node-positive esophageal or gastric cancers. Perioperative chemotherapy improved survival in node-positive esophageal cancer but had no effect in node-negative esophageal and gastric cancer. Discrepancies between clinical and pathological nodal staging were frequent and influenced both survival estimates and treatment allocation. LN removal was associated with survival in esophageal and gastric cancer. Node-negative patients showed increased survival if â‰¥20 nodes were removed, while node-positive esophageal cancer and gastric cancer patients showed no difference in survival beyond 16-19. Lastly, discrepancies between clinical and pathological staging underscore the need for more accurate preoperative diagnostics and highlight the impact of modern perioperative chemotherapy.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739742/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739742')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739742" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Lymph node yield and its impact on survival outcomes: a retrospective multicenter cohort study from Denmark.\nğŸ“– Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739742/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus</b> <span class='badge endo'>Endo</span></div>
                <div class="title"><span class="arrow">â–¶</span>Variability in time to surveillance endoscopy for eosinophilic esophagitis remission and relation to treatment outcomes.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">Patients with eosinophilic esophagitis (EoE) in remission require monitoring, but optimal timing for endoscopic assessment is unknown. We aimed to assess variability in time from remission to surveillance endoscopy and associations with disease outcomes. This retrospective cohort study included patients with EoE who achieved histologic remission (<15 eos/hpf) while on stable treatment and had at least one surveillance endoscopy with biopsy after remission. Time to surveillance was categorized (â‰¤1Â year, 1-2Â years, >2Â years) and compared to a range of EoE clinicopathologic characteristics and disease outcomes. The 91-patient cohort had substantial variability in time to first surveillance endoscopy (mean 1.3â€‰Â±â€‰1.0Â years; median/IQR 1.0/0.6-1.8; range 0.2-7.3). While most patient characteristics were not associated with time to surveillance, larger dilation size at remission correlated with longer surveillance intervals (Râ€‰=â€‰0.36, pâ€‰=â€‰0.03), and EoE Endoscopic Reference Score (EREFS) was inversely associated (Râ€‰= -0.21, pâ€‰=â€‰0.07). Outcomes of EREFS, Index of Severity of EoE, and eosinophil count were similar for <1, 1-2, or 2+ years surveillance intervals. However, numerically fewer patients with endoscopy 2+ years after remission maintained histologic response (59% vs. 78% at â‰¤1Â year and 82% at 1-2Â years; pâ€‰=â€‰0.15) and had more ongoing EoE symptoms (47% vs. 34% at â‰¤1Â year and 24% at 1-2Â years; pâ€‰=â€‰0.26). Surveillance timing in EoE remission varies widely and is largely unexplained by clinical features, except for dilation size. While outcomes were similar across intervals, patients with longer surveillance (>2Â years) had numerically less histologic response and more persistent symptoms, warranting further study.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739741/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739741')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739741" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Variability in time to surveillance endoscopy for eosinophilic esophagitis remission and relation to treatment outcomes.\nğŸ“– Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739741/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Digestive diseases and sciences</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Methodological and Interpretative Considerations in Onishi et al.'s Study of Rebleeding Risk in Suspected Small Bowel Bleeding.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs"></div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739328/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739328')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739328" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Methodological and Interpretative Considerations in Onishi et al.'s Study of Rebleeding Risk in Suspected Small Bowel Bleeding.\nğŸ“– Digestive diseases and sciences\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739328/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Cancer immunology, immunotherapy : CII</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Tumor-specific antibody cocktail treatment suppresses colorectal tumor growth in mice.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                <div class='btm-box'><b>ğŸ’¡ Bottom Line</b><br>Our findings establish a proof-of-concept for individualized, mutation-guided antibody therapies, supporting further development of this approach to improve outcomes in patients with advanced CRC.</div>
                <div class="abs"><b style='color:#3498db;'>BACKGROUND:</b> Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with advanced-stage disease frequently marked by treatment resistance and recurrence. Tumor heterogeneity, driven by the accumulation of somatic mutations, undermines the efficacy of conventional therapies and limits the long-term success of targeted agents. There is an urgent need for new therapeutic strategies that can exploit, rather than be constrained by, this heterogeneity.<br><br><b style='color:#3498db;'>METHODS:</b> We developed a personalized immunotherapeutic pipeline in the syngeneic CT26 murine model of CRC. Briefly, whole exome sequencing identified mutated surface proteins (MSPs) unique to these cells. Of these MSPs, we selected 10 for the generation of MSP-specific polyclonal antibodies (pAbs). These pAbs were tested for specificity and peptide binding to peptides via ELISA, tumor tissue by immunofluorescence, and tumor cells by flow cytometry. Therapeutic efficacy was evaluated in vivo using CT26 tumor-bearing mice treated with the pAb cocktail alone or in combination with anti-PD-1 immune checkpoint blockade. To assess clinical relevance, we analyzed The Cancer Genome Atlas (TCGA) whole exome sequencing data from 100 human CRC patients for MSP prevalence and inter-patient variability.<br><br><b style='color:#3498db;'>RESULTS:</b> The 10-pAb oligoclonal antibody cocktail preparations exhibited additive, high-affinity, tumor-specific binding with minimal reactivity to healthy tissues. In vivo, this pAb cocktail significantly suppressed tumor growth and, when combined with PD-1 blockade, prolonged median survival to over 90Â days in treated mice compared to less than 25Â days in controls. Whole exome sequence data revealed that the majority of human CRC tumors harbored 10 or more MSPs, with minimal overlap between individuals, highlighting the feasibility and necessity of personalized antibody-based therapies.<br><br><b style='color:#3498db;'>CONCLUSION:</b> Our findings establish a proof-of-concept for individualized, mutation-guided antibody therapies, supporting further development of this approach to improve outcomes in patients with advanced CRC.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739229/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739229')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739229" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Tumor-specific antibody cocktail treatment suppresses colorectal tumor growth in mice.\nğŸ“– Cancer immunology, immunotherapy : CII\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739229/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Annals of medicine</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Comparative burden and projections of chewing tobacco-attributable lip/oral cavity and esophageal cancers: global and China-specific trends, 2000-2036.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                <div class='btm-box'><b>ğŸ’¡ Bottom Line</b><br>Chewing tobacco-attributable lip and oral cavity cancer burden in China has risen markedly and is projected to increase further, particularly among males and working-age populations, whereas esophageal cancer burden continues to decline. Integrated prevention strategies are needed to sustain progress and reduce the growing burden.</div>
                <div class="abs"><b style='color:#3498db;'>BACKGROUND:</b> Smokeless tobacco (SLT), particularly chewing tobacco, is an underrecognized public health concern. Its long-term burden and trends, especially in China, remain incompletely quantified.<br><br><b style='color:#3498db;'>METHODS:</b> Using Global Burden of Disease (GBD) 2021 data, we estimated chewing tobacco-attributable deaths, disability-adjusted life years (DALYs), and age-standardized mortality and DALY rates for lip and oral cavity cancer and esophageal cancer (2000-2021), globally and in China. Analyses were stratified by year, sex, and age. Decomposition, age-period-cohort (APC), and Bayesian age-period-cohort (BAPC) models assessed drivers and project trends.<br><br><b style='color:#3498db;'>RESULTS:</b> From 2000 to 2021, chewing tobacco-attributable lip and oral cavity cancer deaths and DALYs nearly doubled globally and in China, with modest rises in age-standardized rates. Esophageal cancer showed slight absolute increases but declining standardized rates. For both cancers, DALYs peaked earlier than deaths. Compared with global patterns, China experienced a steeper increase in age-standardized lip and oral cavity cancer burden, particularly among males, and a larger decline in esophageal cancer burden, especially among females, leading to increasing male predominance. Globally, changes mainly reflected population growth and aging, whereas population growth predominated in China. Projections indicate continued increases in lip and oral cavity cancer burden and further declines in esophageal cancer burden.<br><br><b style='color:#3498db;'>CONCLUSIONS:</b> Chewing tobacco-attributable lip and oral cavity cancer burden in China has risen markedly and is projected to increase further, particularly among males and working-age populations, whereas esophageal cancer burden continues to decline. Integrated prevention strategies are needed to sustain progress and reduce the growing burden.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739173/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739173')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739173" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Comparative burden and projections of chewing tobacco-attributable lip/oral cavity and esophageal cancers: global and China-specific trends, 2000-2036.\nğŸ“– Annals of medicine\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739173/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Avian diseases</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Trends in Necrotic Enteritis and Coccidiosis Control Practices in Canadian Poultry Flocks, 2018-2023.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">Necrotic enteritis (NE) and coccidiosis continue to be diagnosed in poultry in Canada. Since 2013, the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) has been collecting data on antimicrobial use (AMU) and antimicrobial resistance (AMR) in broiler chicken and turkey flocks, with layer flocks added to surveillance in 2021. This study describes enteric disease control strategies utilized in poultry production from 2018 to 2023, based on farm data reported to CIPARS. In broiler chickens, 85% (51.7 mg/kg broiler chicken biomass) of the total quantity of medically important antimicrobials was used for NE control, compared to 51% (28.1 mg/kg turkey biomass) in turkeys and 74% (16 mg/kg layer biomass) in layers. Since 2019, antimicrobial classes used for NE control have decreased following the voluntary elimination of preventive use of macrolides, penicillins, and streptogramins. Bacitracin remained the most frequently used antimicrobial for NE control across all poultry. For coccidiosis control, ionophores were used more frequently than chemical coccidiostats, with a 2.5:1 ratio in broiler chickens (ionophores: 2892.9 kg; chemical coccidiostats: 1126.6 kg) and a 2.4:1 ratio in turkeys (ionophores: 1840.2 kg; chemical coccidiostats: 749.9 kg). Layer flocks used exclusively monensin (39.3 kg) and amprolium (31.6 kg). Over the surveillance time frame, the diversity of coccidiostats used in broiler chickens and turkeys remained stable. Shuttle/dual-control programs (58%) were commonly used in broiler chickens, whereas continuous/straight programs (51%) were predominant in turkeys. Notably, alternative disease control strategies such as vaccination are emerging or continuing. <br><br>Tendencias en las prÃ¡cticas de control de la enteritis necrÃ³tica y la coccidiosis en las explotaciones avÃ­colas de CanadÃ¡, 2018-2023. La enteritis necrÃ³tica (EN) y la coccidiosis continÃºan siendo diagnosticadas en la avicultura de CanadÃ¡. Desde 2013, el Programa Integrado Canadiense de Vigilancia de la Resistencia a los Antimicrobianos (CIPARS) recopila datos sobre el uso de antimicrobianos y la resistencia a los mismos en explotaciones de pollos de engorde y pavos, y desde 2021 tambiÃ©n incluye a las explotaciones de ponedoras. Este estudio describe las estrategias de control de enfermedades entÃ©ricas utilizadas en la producciÃ³n avÃ­cola entre 2018 y 2023, basÃ¡ndose en los datos de las granjas reportados a CIPARS. En pollos de engorde, el 85% (51.7 mg/kg de biomasa) del total de antimicrobianos de importancia mÃ©dica se utilizÃ³ para el control de la enteritis necrÃ³tica, frente al 51% (28.1 mg/kg de biomasa) en pavos y el 74% (16 mg/kg de biomasa) en aves de postura. Desde 2019, la utilizaciÃ³n de clases de antimicrobianos para el control de la enteritis necrÃ³tica ha disminuido tras la eliminaciÃ³n voluntaria del uso preventivo de macrÃ³lidos, penicilinas y estreptograminas. La bacitracina se mantuvo como el antimicrobiano mÃ¡s utilizado para el control de la enteritis necrÃ³tica en todas las especies. Para el control de la coccidiosis, los ionÃ³foros se utilizaron con mayor frecuencia que los coccidiostÃ¡ticos quÃ­micos, en una proporciÃ³n de 2.5:1 en pollos de engorde (ionÃ³foros: 2892.9 kg; coccidiostÃ¡ticos quÃ­micos: 1126.6 kg) y de 2.4:1 en pavos (ionÃ³foros: 1840.2 kg; coccidiostÃ¡ticos quÃ­micos: 749.9 kg). Las explotaciones de aves de postura utilizaron exclusivamente monensina (39.3 kg) y amprolio (31.6 kg). Durante el periodo de vigilancia, la diversidad de coccidiostÃ¡ticos utilizados en pollos de engorde y pavos se mantuvo estable. Los programas de control alterno/dual (58%) se utilizaron comÃºnmente en pollos de engorde, mientras que los programas continuos/directos (51%) predominaron en pavos. Cabe destacar que estÃ¡n surgiendo o se estÃ¡n implementando estrategias alternativas de control de enfermedades, como la vacunaciÃ³n. La vacuna contra </div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41738850/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41738850')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41738850" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Trends in Necrotic Enteritis and Coccidiosis Control Practices in Canadian Poultry Flocks, 2018-2023.\nğŸ“– Avian diseases\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738850/</textarea>
            </div>
        </details></div><div class='sec-group'><h3>ğŸº Liver Track</h3>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Journal of proteome research</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Targeted Quantitative Analysis of Specific Proteins in Cytosolic, Mitochondrial, and Nuclear Fractions Using PRM.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">Mitochondria play a central role in liver physiology by regulating key metabolic processes. Consequently, mitochondrial dysfunction is a hallmark of multiple liver diseases, including steatosis, steatohepatitis, and liver failure following hepatectomy. Subcellular fractionation is widely used to isolate mitochondria from liver cells or tissue; however, the enrichment and purity of isolated fractions are critical to ensure reliable downstream functional and proteomic analyses. Conventional validation methods, such as immunoblotting of organelle-specific markers, are limited by low throughput, restricted sensitivity, and variability. In this study, we present a targeted proteomics strategy based on parallel reaction monitoring (PRM) to quantitatively assess the enrichment of cytosolic, mitochondrial, and nuclear fractions obtained from liver samples using commercial isolation kits. PRM analyses demonstrated robust and compartment-specific enrichment in both PLC/PRF/5 cells and mouse liver tissue. In PLC/PRF/5 cells, high nuclear/cytosolic enrichment was observed for Prelamin A/C, while mitochondrial markers such as ATPase showed strong mitochondrial/cytosolic ratios. Cytosolic markers consistently displayed enrichment in the cytosolic fraction. Similar trends were observed in mouse liver tissue, confirming applicability across biological systems. Overall, these results highlight PRM as a sensitive, reproducible, and cost-effective alternative to immunodetection approaches for evaluating subcellular fraction purity, supporting high-quality mitochondrial preparations for translational hepatology studies.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41740191/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41740191')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41740191" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Targeted Quantitative Analysis of Specific Proteins in Cytosolic, Mitochondrial, and Nuclear Fractions Using PRM.\nğŸ“– Journal of proteome research\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41740191/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Rhode Island medical journal (2013)</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Sigmoid Volvulus in a Healthy Adolescent Male.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">We report the case of a 15-year-old previously healthy male who presented with several days of progressive abdominal pain, vomiting, and anorexia. On arrival to the emergency department, he was hemodynamically stable. Patient's abdominal exam revealed a soft, benign abdomen with right-sided greater than left-sided tenderness. Cross-sectional imaging demonstrated sigmoid volvulus without evidence of pneumatosis, perforation, or free air. He underwent multidisciplinary evaluation by pediatric surgery and gastroenterology, and urgent endoscopic detorsion was performed. Pediatric sigmoid volvulus is rare, accounting for a small minority of large bowel obstructions in this age group. Symptoms may be nonspecific, and exam findings can appear reassuring despite the presence of a high-risk surgical emergency. This case highlights the importance of maintaining a broad differential diagnosis in adolescents presenting with abdominal pain and underscores the role of imaging and multidisciplinary collaboration in timely recognition and management.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41740171/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41740171')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41740171" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Sigmoid Volvulus in a Healthy Adolescent Male.\nğŸ“– Rhode Island medical journal (2013)\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41740171/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus</b> <span class='badge endo'>Endo</span></div>
                <div class="title"><span class="arrow">â–¶</span>Variability in time to surveillance endoscopy for eosinophilic esophagitis remission and relation to treatment outcomes.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">Patients with eosinophilic esophagitis (EoE) in remission require monitoring, but optimal timing for endoscopic assessment is unknown. We aimed to assess variability in time from remission to surveillance endoscopy and associations with disease outcomes. This retrospective cohort study included patients with EoE who achieved histologic remission (<15 eos/hpf) while on stable treatment and had at least one surveillance endoscopy with biopsy after remission. Time to surveillance was categorized (â‰¤1Â year, 1-2Â years, >2Â years) and compared to a range of EoE clinicopathologic characteristics and disease outcomes. The 91-patient cohort had substantial variability in time to first surveillance endoscopy (mean 1.3â€‰Â±â€‰1.0Â years; median/IQR 1.0/0.6-1.8; range 0.2-7.3). While most patient characteristics were not associated with time to surveillance, larger dilation size at remission correlated with longer surveillance intervals (Râ€‰=â€‰0.36, pâ€‰=â€‰0.03), and EoE Endoscopic Reference Score (EREFS) was inversely associated (Râ€‰= -0.21, pâ€‰=â€‰0.07). Outcomes of EREFS, Index of Severity of EoE, and eosinophil count were similar for <1, 1-2, or 2+ years surveillance intervals. However, numerically fewer patients with endoscopy 2+ years after remission maintained histologic response (59% vs. 78% at â‰¤1Â year and 82% at 1-2Â years; pâ€‰=â€‰0.15) and had more ongoing EoE symptoms (47% vs. 34% at â‰¤1Â year and 24% at 1-2Â years; pâ€‰=â€‰0.26). Surveillance timing in EoE remission varies widely and is largely unexplained by clinical features, except for dilation size. While outcomes were similar across intervals, patients with longer surveillance (>2Â years) had numerically less histologic response and more persistent symptoms, warranting further study.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739741/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739741')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739741" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Variability in time to surveillance endoscopy for eosinophilic esophagitis remission and relation to treatment outcomes.\nğŸ“– Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739741/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Inflammatory bowel diseases</b>  ğŸ”¥</div>
                <div class="title"><span class="arrow">â–¶</span>Comparing diagnostic accuracy of transperineal ultrasound using microconvex probe versus conventional linear probe to predict rectal histoendoscopic activity in ulcerative colitis: a paired prospective, head-to-head comparative study.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> âœ… ê¸°ì¡´ ì¹˜ë£Œë³´ë‹¤ ìš°ìˆ˜ (ìš°ì„  ê³ ë ¤)</div>
        </div>
                <div class='btm-box'><b>ğŸ’¡ Bottom Line</b><br>TPUS provides clinically relevant, noninvasive assessment of rectal inflammation in UC. While microconvex TPUS offers technical advantages-particularly axial-plane assessment of posterior wall thickness with favorable diagnostic trends-no single probe demonstrated uniform superiority. These findings highlight the complementary roles of linear and microconvex probes and support ongoing standardization of TPUS.</div>
                <div class="abs"><b style='color:#3498db;'>BACKGROUND AND AIMS:</b> Prior studies have reported variable diagnostic accuracy of transperineal ultrasound (TPUS) in ulcerative colitis (UC) using linear and/or microconvex probes. This study directly compared these probes for predicting rectal histoendoscopic activity.<br><br><b style='color:#3498db;'>METHODS:</b> Adults with UC prospectively underwent transabdominal ultrasound (TAS) with TPUS using linear followed by microconvex probes by blinded operators. Rectal total wall thickness (TWT), vascularity (Modified Limberg score [MLS]), and Milan ultrasound criteria (MUC) were recorded. Receiver operating characteristic analysis determined area under the curve (AUC) for endoscopic (Ulcerative Colitis Endoscopic Index of Severity >1) and histologic (Nancy Index >1) activity, with paired AUC comparisons.<br><br><b style='color:#3498db;'>RESULTS:</b> Ninety-seven patients (32% female; age 18-70â€‰years) were included. For endoscopic activity, TPUS outperformed TAS. Microconvex TPUS showed numerically higher AUCs for selected parameters (TWT: 0.77; vascularity: 0.78; MUC: 0.81) compared with linear TPUS (TWT: 0.75; vascularity: 0.71; MUC: 0.77), although head-to-head differences were not consistently statistically significant. For histologic activity, microconvex and linear TPUS demonstrated comparable performance (AUC range 0.66-0.80). Axial-plane posterior wall thickness assessment with the microconvex probe showed favorable trends over longitudinal measurements (endoscopic: Î”AUC -0.071, Pâ€‰=â€‰.074; histologic: Î”AUC 0.081, Pâ€‰=â€‰.08). Vascularity-based metrics were consistently superior on TPUS compared with TAS, irrespective of probe type.<br><br><b style='color:#3498db;'>CONCLUSION:</b> TPUS provides clinically relevant, noninvasive assessment of rectal inflammation in UC. While microconvex TPUS offers technical advantages-particularly axial-plane assessment of posterior wall thickness with favorable diagnostic trends-no single probe demonstrated uniform superiority. These findings highlight the complementary roles of linear and microconvex probes and support ongoing standardization of TPUS.<br><br>This study compared two ultrasound probes for assessing rectal inflammation in ulcerative colitis. Transperineal ultrasound enabled accurate, noninvasive monitoring, with the microconvex probe showing slightly better visualization and diagnostic trends, while overall performance was comparable between probes.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739522/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739522')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739522" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Comparing diagnostic accuracy of transperineal ultrasound using microconvex probe versus conventional linear probe to predict rectal histoendoscopic activity in ulcerative colitis: a paired prospective, head-to-head comparative study.\nğŸ“– Inflammatory bowel diseases\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739522/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>International journal of clinical pharmacy</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Development and validation of a LASSO-logistic regression model for predicting subtherapeutic infliximab trough concentrations in patients with Crohn's disease.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                <div class='btm-box'><b>ğŸ’¡ Bottom Line</b><br>The proposed LASSO-logistic regression model demonstrates promising predictive performance for identifying subtherapeutic IFX exposure in CD patients. By leveraging readily available clinical data, it enables early risk stratification and individualized therapeutic decision-making, thereby facilitating more effective treatment optimization.</div>
                <div class="abs"><b style='color:#3498db;'>BACKGROUND:</b> Infliximab (IFX), a monoclonal antibody that neutralizes tumor necrosis factor-Î±, is widely used as a biologic treatment for Crohn's disease (CD). Despite its established efficacy, a substantial proportion of patients develop subtherapeutic IFX trough concentrations (<â€‰3Â Î¼g/mL), leading to diminished clinical response and treatment failure. Early identification of high-risk individuals remains challenging due to the multifactorial nature of IFX pharmacokinetics.<br><br><b style='color:#3498db;'>AIM:</b> This study integrated Least Absolute Shrinkage and Selection Operator (LASSO)-based variable selection with multivariable logistic regression to identify CD patients at risk for subtherapeutic IFX trough levels during induction.<br><br><b style='color:#3498db;'>METHOD:</b> A total of 347 patients diagnosed with CD who commenced IFX induction therapy at the Sixth Affiliated Hospital of Sun Yat-sen University from January to December 2023 were retrospectively reviewed in this study. Comprehensive demographic, clinical, and biochemical data were retrieved from electronic records. Variable selection was performed using the Least Absolute Shrinkage and Selection Operator (LASSO), after which a multivariable logistic model was developed. Model discrimination, calibration and clinical usefulness were assessed through the area under the receiver operating characteristic curve (AUC), calibration curves, decision curve analysis (DCA) and clinical impact curves (CIC).<br><br><b style='color:#3498db;'>RESULTS:</b> Of the 347 participants, 148 (42.7%) exhibited subtherapeutic IFX trough concentrations. LASSO and multivariable logistic analyses identified four independent predictors: older age at diagnosis (>â€‰40Â years), elevated anti-drug antibody levels, higher erythrocyte sedimentation rate and reduced albumin (Pâ€‰<â€‰0.05). The model demonstrated an AUC of 0.737 (95% CI 0.684-0.790), with a bootstrap-adjusted AUC of 0.726 (95% CI 0.697-0.739) based on 1000 resamples. Calibration demonstrated close alignment with observed outcomes, validated by a non-significant Hosmer-Lemeshow test (Ï‡<br><br><b style='color:#3498db;'>CONCLUSION:</b> The proposed LASSO-logistic regression model demonstrates promising predictive performance for identifying subtherapeutic IFX exposure in CD patients. By leveraging readily available clinical data, it enables early risk stratification and individualized therapeutic decision-making, thereby facilitating more effective treatment optimization.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739409/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739409')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739409" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Development and validation of a LASSO-logistic regression model for predicting subtherapeutic infliximab trough concentrations in patients with Crohn's disease.\nğŸ“– International journal of clinical pharmacy\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739409/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>International journal of clinical pharmacy</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Oral low-dose methotrexate improves infliximab pharmacokinetics, immunogenicity, and endoscopic outcomes in Crohn's disease: a propensity score-adjusted real-world study.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> âš ï¸ ê¸°ì¡´ ì¹˜ë£Œ ìœ ì§€ ê¶Œì¥</div>
        </div>
                <div class='btm-box'><b>ğŸ’¡ Bottom Line</b><br>In patients with Crohn's disease, oral low-dose methotrexate combined with infliximab was associated with significantly improved endoscopic remission at week 26 compared to infliximab monotherapy, without a statistically significant increase in adverse events.</div>
                <div class="abs"><b style='color:#3498db;'>INTRODUCTION:</b> The effectiveness of infliximab in Crohn's disease is often compromised by immunogenicity. Oral low-dose methotrexate may offer a promising strategy to optimize infliximab therapy, yet its real-world effectiveness and safety remain uncertain.<br><br><b style='color:#3498db;'>AIM:</b> This study aimed to compare the effectiveness and safety of infliximab plus oral low-dose methotrexate versus infliximab monotherapy.<br><br><b style='color:#3498db;'>METHOD:</b> In this single-center retrospective cohort study, 119 patients with Crohn's disease received either infliximab monotherapy (nâ€‰=â€‰99) or combination therapy with oral low-dose methotrexate (10-15Â mg/week; nâ€‰=â€‰20). The primary outcome was endoscopic remission (Simple Endoscopic Score for Crohn's Diseaseâ€‰â‰¤â€‰2) at week 26. Propensity score methods, including nearest-neighbor matching and inverse probability of treatment weighting, were used to adjust for confounding. Conditional and weighted logistic regression were used to estimate treatment effects.<br><br><b style='color:#3498db;'>RESULTS:</b> After propensity score adjustment, combination therapy was associated with a significantly higher rate of endoscopic remission (aOR 3.70, 95% CI 1.16-11.75; Pâ€‰=â€‰0.027). No significant differences were observed in endoscopic response or clinical outcomes. In a pharmacokinetic subgroup, combination therapy resulted in numerically higher infliximab trough concentrations and no detectable anti-drug antibodies (0% vs. 16.7%). Higher trough concentrations were associated with endoscopic remission (Pâ€‰=â€‰0.033). The incidence of elevated liver enzymes was higher in the combination group (20.0% vs. 4.0%), but this difference was not statistically significant after adjustment (Pâ€‰=â€‰0.058).<br><br><b style='color:#3498db;'>CONCLUSION:</b> In patients with Crohn's disease, oral low-dose methotrexate combined with infliximab was associated with significantly improved endoscopic remission at week 26 compared to infliximab monotherapy, without a statistically significant increase in adverse events.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739407/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739407')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739407" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Oral low-dose methotrexate improves infliximab pharmacokinetics, immunogenicity, and endoscopic outcomes in Crohn's disease: a propensity score-adjusted real-world study.\nğŸ“– International journal of clinical pharmacy\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739407/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Digestive diseases and sciences</b> <span class='badge endo'>Endo</span></div>
                <div class="title"><span class="arrow">â–¶</span>External Validation of an AI-Based Colonoscopy Quality Assessment Tool in Japanese Clinical Practice: A Pilot Study.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                <div class='btm-box'><b>ğŸ’¡ Bottom Line</b><br>AI-CQ demonstrated feasibility for measuring colonoscopy quality metrics in Japanese practice, though with reduced correlation compared to US validation. Given the pilot nature of this study, these findings should be interpreted as exploratory. Novel metrics like HQ-WT showed promising associations with procedural quality indicators, warranting further validation in larger cohorts.</div>
                <div class="abs"><b style='color:#3498db;'>BACKGROUND:</b> While AI-assisted polyp detection has advanced significantly, comprehensive AI-based colonoscopy quality assessment tools remain limited. This study aimed to externally validate an AI-based colonoscopy quality assessment tool (AI-CQ) in Japanese clinical practice.<br><br><b style='color:#3498db;'>METHODS:</b> This retrospective study analyzed 40 screening colonoscopy procedures at a tertiary endoscopy hospital in Japan. All videos were recorded using Olympus equipment from anal insertion to complete withdrawal. AI-CQ measurements were compared with manual assessments by a certified endoscopist. Metrics evaluated included insertion time (IT), withdrawal time (WT), withdrawal time minus polypectomy time, and high-quality withdrawal time (HQ-WT).<br><br><b style='color:#3498db;'>RESULTS:</b> AI-CQ successfully identified cecal intubation in 97.5% of cases. Correlations between manual and AI measurements were moderate for IT (Ïâ€‰=â€‰0.48, pâ€‰=â€‰0.0025) and strong for WT (Ïâ€‰=â€‰0.70, pâ€‰<â€‰0.001). HQ-WT differed significantly by endoscopist experience (388 vs. 273Â s, pâ€‰=â€‰0.025) and polyp detection status (497 vs. 298Â s, pâ€‰<â€‰0.001). These associations remained significant even after adjusting for manual polyp observation time.<br><br><b style='color:#3498db;'>CONCLUSION:</b> AI-CQ demonstrated feasibility for measuring colonoscopy quality metrics in Japanese practice, though with reduced correlation compared to US validation. Given the pilot nature of this study, these findings should be interpreted as exploratory. Novel metrics like HQ-WT showed promising associations with procedural quality indicators, warranting further validation in larger cohorts.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739329/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739329')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739329" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ External Validation of an AI-Based Colonoscopy Quality Assessment Tool in Japanese Clinical Practice: A Pilot Study.\nğŸ“– Digestive diseases and sciences\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739329/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Digestive diseases and sciences</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Methodological and Interpretative Considerations in Onishi et al.'s Study of Rebleeding Risk in Suspected Small Bowel Bleeding.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs"></div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739328/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739328')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739328" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Methodological and Interpretative Considerations in Onishi et al.'s Study of Rebleeding Risk in Suspected Small Bowel Bleeding.\nğŸ“– Digestive diseases and sciences\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739328/</textarea>
            </div>
        </details></div><div class='sec-group'><h3>ğŸ§¬ Biliary/Pancreas</h3>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Location Matters in IPMN: Clinicopathological differences, malignancy risk and oncological outcomes for lesions located in head vs body and tail of the pancreas.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                <div class='btm-box'><b>ğŸ’¡ Bottom Line</b><br>Ventral IPMNs are more commonly resected and show higher rates of intestinal epithelium and malignancy compared with dorsal lesions. A MPD size > 5 mm in IPMNs of the dorsal pancreas is associated with a substantial risk of malignancy.</div>
                <div class="abs"><b style='color:#3498db;'>BACKGROUND:</b> The clinico-pathological characteristics and accuracy of the current International Association of Pancreatology guidelines for IPMN in relation to its location within the pancreas has not been investigated.<br><br><b style='color:#3498db;'>METHODS:</b> 751 patients who underwent pancreatic resection for IPMN in two tertiary referral centers were retrospectively categorized into subgroups according to location within the pancreas. Likelihood of worrisome features, high-risk stigmata (HRS), clinico-pathological features and presence of malignancy were compared.<br><br><b style='color:#3498db;'>RESULTS:</b> 480 (64%) patients had IPMN in the ventral pancreas (i.e. head, uncinate process and neck), and 271(36%) in the dorsal gland (i.e. body/tail). Malignancy was present in 54% (n = 259) of patients with ventral IPMN and in 39% (n = 107) of those with dorsal lesions (p < 0.0001). There was a significantly higher proportion of intestinal epithelium in ventral IPMNs when compared to those in the dorsal pancreas, both in the general cohort and in invasive cancer group (27% vs 15%, OR: 1.94 95%CI:1.16-3.24 p = 0.006 and 31% vs 22% OR 1.52 95%CI: 0.77-3, p = 0.24 respectively). Patients with ventral IPMN more frequently presented with HRS (49%vs 37%, p < 0.001), while dorsal IPMN often showed only worrisome features (54%vs 43%, p = 0.06). ROC curve analysis identified optimal cut-off values for main pancreatic duct diameter of 9 mm in ventral IPMNs and 5 mm in dorsal IPMNs for malignancy prediction.<br><br><b style='color:#3498db;'>CONCLUSIONS:</b> Ventral IPMNs are more commonly resected and show higher rates of intestinal epithelium and malignancy compared with dorsal lesions. A MPD size > 5 mm in IPMNs of the dorsal pancreas is associated with a substantial risk of malignancy.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41735113/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41735113')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41735113" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Location Matters in IPMN: Clinicopathological differences, malignancy risk and oncological outcomes for lesions located in head vs body and tail of the pancreas.\nğŸ“– Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41735113/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>JAMA surgery</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Contemporary Outcomes of Cholecystectomy.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs"><b style='color:#3498db;'>IMPORTANCE:</b> Cholecystectomy is among the most common surgical procedures in the US, yet as patient complexity has increased and surgical techniques have evolved, contemporary trends in complication rates remain understudied.<br><br><b style='color:#3498db;'>OBJECTIVE:</b> To evaluate changes in postoperative outcomes and complication rates following minimally invasive cholecystectomy among Medicare beneficiaries between 2011 and 2021.<br><br><b style='color:#3498db;'>DESIGN, SETTING, AND PARTICIPANTS:</b> This cohort study used Medicare fee-for-service claims data from 2011 to 2021 to identify beneficiaries undergoing inpatient minimally invasive (laparoscopic or robotic) cholecystectomy. Risk-adjusted outcomes were estimated using multivariable logistic regression with marginal effects, adjusting for demographics, comorbidities, biliary diagnosis, admission type, and year. Adjusted estimates for length of stay were estimated using multivariable Poisson regression with marginal effects, adjusting for the same covariates. Data were analyzed between March and August 2025.<br><br><b style='color:#3498db;'>MAIN OUTCOMES AND MEASURES:</b> Key outcomes included length of stay, 30-day readmission, complications, serious complications, 30-day mortality, and in-hospital mortality. Specific complications, such as intraoperative hemorrhage, bile duct injury, transfusion, percutaneous drainage, urinary tract infection, and deep venous thrombosis, were also assessed.<br><br><b style='color:#3498db;'>RESULTS:</b> Among 516â€¯372 Medicare fee-for-service beneficiaries (mean [SD] age, 74.8 [9.8] years; 52.4% female), the proportion who had unplanned (vs elective) admissions for cholecystectomy increased from 78.8% in 2011 to 90.1% in 2021 (Pâ€‰<â€‰.001), alongside increases in Elixhauser comorbidity burden. Risk-adjusted rates of overall complications decreased from 21.5% (95% CI, 21.3%-21.7%) in 2011 to 16.5% (95% CI, 16.4%-16.7%) in 2021 (Pâ€‰<â€‰.001), and serious complications declined from 12.3% (95% CI, 12.2%-12.5%) to 7.0% (95% CI, 6.9%-7.1%) (Pâ€‰<â€‰.001). Specific complications also improved, including intraoperative hemorrhage (1.07% [95% CI, 1.01%-1.13%] to 0.54% [95% CI, 0.50%-0.58%]), blood transfusion (5.47% [95% CI, 5.34%-5.60%] to 1.87% [95% CI, 1.80%-1.94%]), and bile duct injury (0.19% [95% CI, 0.16%-0.21%] to 0.12% [95% CI, 0.11%-0.14%]) (all Pâ€‰<â€‰.001). However, rates of postoperative percutaneous drainage increased from 1.32% (95% CI, 1.26%-1.37%) to 2.91% (95% CI, 2.81%-3.01%) (Pâ€‰<â€‰.001).<br><br><b style='color:#3498db;'>CONCLUSIONS AND RELEVANCE:</b> In this study of Medicare beneficiaries undergoing inpatient minimally invasive cholecystectomy, surgical complication rates, including bile duct injury, declined substantially from 2011 to 2021 despite increasing patient complexity. These improvements may reflect improved technique, overcoming the initial learning curve, or the cumulative influence of quality improvement efforts. The increasing use of drainage may reflect evolving surgical practice rather than declining quality, which underscores the need for continued investigation and surveillance.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41739485/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41739485')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41739485" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Contemporary Outcomes of Cholecystectomy.\nğŸ“– JAMA surgery\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41739485/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Zoological science</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Non-Contiguous and Multi-Regional Expression of Pancreas-Related Genes along the Lancelet Gut.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">Deuterostomes generally share a functional digestive system involving the sequential steps of ingestion, digestion, absorption, and elimination along their one-way gut. Previous gene expression studies on pancreas-related exocrine digestive enzymes (XDEs), pancreas-related transcription factors (TFs), and ParaHox genes in the ascidian </div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41738869/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41738869')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41738869" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Non-Contiguous and Multi-Regional Expression of Pancreas-Related Genes along the Lancelet Gut.\nğŸ“– Zoological science\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41738869/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Frontiers in immunology</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Prognostic value of PD-L1 expression on tumor-infiltrating immune cells and neutrophil-to-lymphocyte ratio in patients with biliary tract cancer.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                <div class='btm-box'><b>ğŸ’¡ Bottom Line</b><br>PD-L1 expression on TIICs and dynamic NLR may be indicative of prognosis in BTC and could provide insights into immune status and response to immunotherapy after recurrence. These findings highlight the potential value of integrating local immune contexture with systemic inflammatory markers, but further validation in larger and prospective cohorts is warranted.</div>
                <div class="abs"><b style='color:#3498db;'>BACKGROUND:</b> The expression of Programmed Death-Ligand 1 (PD-L1) on tumor-infiltrating immune cells (TIICs), plays a crucial role in tumor progression and immune evasion, impacting both the natural immune response and immune-targeted therapeutic strategies. The neutrophil-to-lymphocyte ratio (NLR) has also gained attention as a potential predictive biomarker for immunotherapy efficacy, as it may correlate with treatment outcomes.<br><br><b style='color:#3498db;'>OBJECTIVE:</b> To examine the expression of PD-L1 on TIICs and assess the influence of PD-L1 and NLR on immunotherapy outcomes following biliary tract cancers (BTC) recurrence.<br><br><b style='color:#3498db;'>METHODS:</b> From January 1, 2017, to January 1, 2020, this study enrolled 239 patients from the Department of Pancreaticobiliary Surgery at Sun Yat-sen University Cancer Center. Immunohistochemical analysis of PD-L1 on TIICs was conducted on pathological tissue sections from these patients. Clinical data, including overall survival (OS), disease-free survival (DFS), and pathological findings, were collected during follow-up. Statistical analyses were performed to assess outcomes related to the study objectives. Furthermore, data from The Cancer Genome Atlas (TCGA) were utilized to examine PD-L1 expression profiles and related information.<br><br><b style='color:#3498db;'>RESULTS:</b> Tumor stage did not differ significantly (P = 0.173), while metastasis stage approached significance (P = 0.093), with a higher proportion of M0 cases in the PD-L1 low group. Univariate analysis revealed vascular tumor thrombus, tumor differentiation, node stage, and preoperative CA199 levels as factors associated with DFS. Notably, vascular tumor thrombus (HR = 1.791, P = 0.002), moderate tumor differentiation (HR = 0.537, P = 0.002), and elevated preoperative CA199 levels (>35, HR = 1.624, P = 0.009) emerged as significant risk factors. Elevated NLR demonstrated a significant association with reduced DFS (HR = 1.54, p = 0.017 one week prior; HR = 1.70, p = 0.007 one month after) and diminished OS (HR = 2.30, p < 0.001 one week prior; HR = 1.94, p = 0.005 one month after). Exploratory analysis in a limited immunotherapy subgroup (n=35) suggested patients exhibiting high PD-L1 levels on TIICs may be associated with worse OS following immunotherapy after recurrence (HR = 3.03, p = 0.036). High NLR, both one month before recurrence (HR = 2.23, p = 0.015) and one month after recurrence (HR = 2.10, p = 0.027), correlated with decreased OS.<br><br><b style='color:#3498db;'>CONCLUSION:</b> PD-L1 expression on TIICs and dynamic NLR may be indicative of prognosis in BTC and could provide insights into immune status and response to immunotherapy after recurrence. These findings highlight the potential value of integrating local immune contexture with systemic inflammatory markers, but further validation in larger and prospective cohorts is warranted.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41737495/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41737495')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41737495" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Prognostic value of PD-L1 expression on tumor-infiltrating immune cells and neutrophil-to-lymphocyte ratio in patients with biliary tract cancer.\nğŸ“– Frontiers in immunology\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41737495/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Innovation (Cambridge (Mass.))</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">Although circulating cell-free DNA (cfDNA) methylation has emerged as the mainstream approach in multi-cancer detection blood tests (MCDBTs), the potential of integrating proteins and mutations, to enhance its performance remains unclear. The PROMISE study (NCT04972201) was conducted to investigate the feasibility of a multi-omics integration strategy in MCDBTs across nine types of cancers in head and neck (excluding nasopharynx), esophagus, lung, stomach, liver, biliary tract, pancreas, colorectum, and ovary. Blood samples were prospectively collected from 1,706 participants (840 non-cancer; 866 cancer) and then randomly divided into training and validation sets. The complementarity between various omics were investigated, and specific omics features were carefully selected for further multimodal model construction. The methylation-based classifier outperformed both the mutation-based and protein-based classifiers. As 95.0% of cancer cases detected by the mutation-based classifier were simultaneously identified by the methylation-based classifier, while 14.0% of the protein-positive samples were missed, protein markers may provide complementary value to the methylation-based classifier. Compared with the methylation-based classifier, the multimodal classifier combining methylation and protein features exhibited an improved sensitivity of 75.1% (95% confidence interval [CI], 69.3%-80.3%) at the same specificity of 98.8% with the accuracy of top predicted origin (TPO1) of 73.1% (95% CI, 66.2%-79.2%). Notably, the TPO1 accuracy reached 100% in liver and ovarian cancers with negative results of the methylation-based classifier. Collectively, these data suggest that the integration of protein markers in the multimodal classifier can offer additional benefits to the methylation-based classifier, particularly in identifying liver and ovarian cancers.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41737326/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41737326')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41737326" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study.\nğŸ“– Innovation (Cambridge (Mass.))\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41737326/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Frontiers in immunology</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Multifunctional theranostic magnetic PLGA nanoparticles encapsulating cyclosporine A: addressing challenges in pancreas transplantation for type 1 diabetes.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">Type 1 Diabetes (T1D) is a high-incidence chronic autoimmune disease, with patients requiring lifelong insulin therapy. In the most severe cases, pancreas transplantation (PTA) arises as the first choice of treatment for these patients in the hope of achieving insulin independence. However, the long-term success of PTA is hindered by ischemia-reperfusion injury (IRI) and immune rejection, both of which limit graft survival. To address these challenges, we have developed multifunctional theranostic nanoparticles (t-PLGA NPs) co-encapsulating Fe</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41737232/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41737232')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41737232" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Multifunctional theranostic magnetic PLGA nanoparticles encapsulating cyclosporine A: addressing challenges in pancreas transplantation for type 1 diabetes.\nğŸ“– Frontiers in immunology\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41737232/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>The American surgeon</b> </div>
                <div class="title"><span class="arrow">â–¶</span>A Novel Approach to Complex Splenic Hilar Aneurysms: ICG-Guided Partial Spleen Preservation Combined With Distal Pancreatectomy.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">BackgroundSplenic hilar aneurysms exceeding 2Â cm in diameter typically warrant surgical intervention given their elevated risk of fatal rupture. While complete splenectomy has historically been the conventional approach to mitigate operative complexity, this procedure carries significant postoperative concerns including compromised immune function and increased thrombotic risks associated with splenic absence.Case presentationIn two cases of splenic artery aneurysms (SAAs) deeply embedded within the pancreatic tail at the splenic hilar region, we performed laparoscopic resection of the splenic artery aneurysm and distal pancreas. Intraoperative indocyanine green (ICG) fluorescence imaging was employed to map perfusion patterns of the spleen, demonstrating sequential greening and subsequent fading of the splenic upper pole. This confirmed preserved arterial inflow and venous drainage, thus confirming maintained vascularization following splenic artery ligation. The patients achieved an uneventful recovery and were discharged without complications.ConclusionsWe described the first use of a technique that integrates distal pancreatectomy with ICG-guided partial splenic preservation for complex splenic hilar aneurysms. This strategy facilitates precise resection of the aneurysm and non-viable spleen, thereby maximizing functional preservation and establishing itself as a promising option for managing these challenging lesions.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41736514/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41736514')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41736514" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ A Novel Approach to Complex Splenic Hilar Aneurysms: ICG-Guided Partial Spleen Preservation Combined With Distal Pancreatectomy.\nğŸ“– The American surgeon\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41736514/</textarea>
            </div>
        </details>
        <details class="paper-item">
            <summary>
                <div class="meta">  <b>Molecular aspects of medicine</b> </div>
                <div class="title"><span class="arrow">â–¶</span>Metabolic dysregulation: Its role in diabetes mellitus and cancers.</div>
            </summary>
            <div class="content">
                
        <div class='clinical-note'>
            <div style='margin-bottom:8px;'><b>ğŸ‘¨â€âš•ï¸ Clinical Translation:</b> ğŸ‘‰ ê°œë³„ ì„ìƒ íŒë‹¨ í•„ìš”</div>
            <div><b>âš¡ Tomorrow's Action:</b> ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”</div>
        </div>
                
                <div class="abs">Diabetes mellitus (DM) is a significant risk factor for several cancers, particularly cancers of the liver, pancreas, and endometrium. This review aims to understand the connections between diabetic pathophysiology and cancer biology. We synthesize how core metabolic disturbances-hyperinsulinemia, hyperglycemia, and inflammation-promote tumorigenesis by dysregulating canonical oncogenic pathways such as IGF-1 signaling, DNA damage repair, and immunometabolism. Subsequently, we focus on how key molecular integrators-such as p38 MAPK, Wnt/Î²-catenin, and the AGEs-RAGE axis-mediate metabolic stress to confer proliferative and invasive advantages to tumor cells. However, a direct translational application of these mechanisms, particularly in the context of repurposing antidiabetic drugs for cancer therapy, remains challenging due to inconsistent clinical outcomes. To address this gap, we suggest that a fundamental shift in approach is required. We propose that future research must move beyond simple pathway categorization and instead utilize spatial analysis techniques to reveal how diabetic metabolites reshape the tumor microenvironment (TME). By integrating single-cell and spatial omics technologies, the field can begin to map the precise cellular niches within tumors where diabetic metabolites exacerbate malignant progression and foster treatment resistance. This perspective is essential for developing targeted strategies to mitigate cancer risk and improve outcomes for the expanding population of patients with DM and cancer.</div>
                <div class="btns">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/41734405/" target="_blank" class="btn pub">ğŸ”— PubMed</a>
                    <button onclick="copyShare('41734405')" class="btn shr">ğŸ“¤ ì¹´í†¡ê³µìœ </button>
                </div>
                <textarea id="s_41734405" style="display:none;">ğŸ“„ [GI Intel]\nğŸ“Œ Metabolic dysregulation: Its role in diabetes mellitus and cancers.\nğŸ“– Molecular aspects of medicine\nâš¡ Action: ğŸ§ ë°ì´í„° ì¶”ê°€ í™•ì¸ í•„ìš”\nğŸ”— https://pubmed.ncbi.nlm.nih.gov/41734405/</textarea>
            </div>
        </details></div>
    </div>
    <footer style="text-align:center; padding:20px; color:#95a5a6; font-size:0.8rem;">ğŸš€ Project: MedProductive - AI Decision Support</footer>
    <script>
        function toggleF() {
            const btn = document.getElementById('fBtn'); btn.classList.toggle('active');
            const isF = btn.classList.contains('active');
            document.querySelectorAll('.paper-item').forEach(p => {
                p.style.display = isF ? (p.querySelector('.badge-guideline') ? 'block' : 'none') : 'block';
            });
        }
        function copyShare(id) {
            const el = document.getElementById('s_'+id);
            const val = el.value.replace(/\\n/g, '\n');
            navigator.clipboard.writeText(val).then(() => alert("âœ… ì„ìƒ íŒë‹¨ í¬í•¨ í…ìŠ¤íŠ¸ ë³µì‚¬ ì™„ë£Œ!"));
        }
        new Chart(document.getElementById('c1'), { type:'bar', data:{ labels:["GI", "Liver", "Biliary/Pancreas"], datasets:[{data:[7, 8, 8], backgroundColor:'#3498db'}] }, options:{indexAxis:'y', plugins:{legend:{display:false}}} });
        new Chart(document.getElementById('c2'), { type:'doughnut', data:{ labels:["GI", "Liver", "Biliary/Pancreas"], datasets:[{data:[7, 8, 8], backgroundColor:['#e74c3c','#f1c40f','#2ecc71']}] }, options:{plugins:{legend:{position:'bottom'}}} });
    </script>
</body>
</html>
